ReviewClinical ophthalmology (Auckland, N.Z.)2021
Presbyopia - A Review of Current Treatment Options and Emerging Therapies.
Review in Clinical ophthalmology (Auckland, N.Z.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Efficacy and safety of pilocarpine for the treatment of presbyopia: a systematic review and meta‑analysis of randomized controlled trials.Scientific reports · 2026Pooled it
- Design of Progressive Addition Lens for Presbyopia: A Systematic Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Pooled it
- Surgical interventions for presbyopia.The Cochrane database of systematic reviews · 2025Pooled it
- Comparison of Clinical Performance and Fit Success of Lehfilcon A and Lotrafilcon B Daily Wear Monthly Replacement Silicone Hydrogel Multifocal Contact Lenses in Patients with Presbyopia.Clinical optometry · 2026Trial
- Six-month performance and safety of an iris-fixated multifocal intraocular lens for presbyopia correction in phakic eyes.Journal of cataract and refractive surgery · 2025Trial
- Randomized controlled trial on the efficacy and safety of the combination therapy of topical 0.1% finasteride - 5% Minoxidil in male androgenetic alopecia.Archives of dermatological research · 2025Trial
- Extract fromNutrients · 2024Trial
- Combination Low-Dose Pilocarpine/Diclofenac Sodium and Pilocarpine Alone for Presbyopia: Results of a Randomized Phase 2b Clinical Trial.Clinical ophthalmology (Auckland, N.Z.) · 2024Trial
- Defocus Curve and Satisfaction of Patients with Presbyopia After LASIK Using the Differential Modulation of Binocular Longitudinal Spherical Aberration.Clinical ophthalmology (Auckland, N.Z.) · 2023Trial
- Subjective clinical visual disturbance scores correlation with simulated vehicle headlight halo in presbyopia-correcting intraocular lenses.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Visual and refractive outcomes of eyes with low corneal astigmatism implanted with low toric or non-toric trifocal intraocular lenses.BMC ophthalmology · 2026Article
- A Novel Test of Dynamic Visual Function: Comparison Between Presbyopic and Non-Presbyopic Individuals.Diagnostics (Basel, Switzerland) · 2026Article
- Evaluating the Efficacy and Safety of the LASIK Nonlinear Aspheric Micro-Monovision Surgery (Laser Blended Vision Surgery) in Correcting Presbyopia Among the Saudi Population.Healthcare (Basel, Switzerland) · 2026Article
- Yuvezzi™ (carbachol and brimonidine tartrate) dual-agent eyedrops: a new option for presbyopia.Annals of medicine and surgery (2012) · 2026Article
- Three-month outcomes of PresbyEDOF: A retrospective case study evaluating a laser-based corneal solution for presbyopia correction.Indian journal of ophthalmology · 2026Article
- Comments on efficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia - A multicentric clinical trial.Indian journal of ophthalmology · 2026Article
- Bilateral implantation of liberty trifocal and trifocal toric intraocular lens.BMC ophthalmology · 2026Article
- Expanding access to near-vision correction services: WHO targets, tools, and initiatives.Community eye health · 2026Article
- Beyond glasses: FDA approval of VIZZ (aceclidine) transforming presbyopia management.Annals of medicine and surgery (2012) · 2026Article
- Preclinical Evaluation of a Pilocarpine-(R)-Lipoic Acid Eye Drop for Presbyopia.Translational vision science & technology · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Presbyopia is a common age-related vision disorder characterized by a progressive inability to focus on near objects. If uncorrected or under-corrected, presbyopia can significantly impact patients' quality of life. Presbyopia represents an area of considerable unmet need due to its rising prevalence worldwide as the population ages, the high proportion of under-treated individuals in some parts of the world, and the limitations of currently available corrective methods. Progressive or bifocal spectacles are associated with peripheral blur, a restricted visual field and impaired depth perception, which have been linked to an increased risk of falls in the elderly. Contact lens options can be difficult to maintain due to the development of age-related dry eye symptoms and reduced manual dexterity. Other corrective methods involve surgical interventions that modify the optics of the cornea, replace the crystalline lens, or attempt to restore active accommodation. While patients undergoing surgery report satisfactory outcomes post-operatively, many of them eventually require reading glasses. Non-invasive therapies with novel mechanisms of action are currently being investigated; these include miotic agents and UNR844, a lipoic acid choline ester. In this narrative review, available evidence on presbyopia prevalence, quality of life impact and risk factors are described, with a focus on observational studies in non-clinical settings. The diagnosis pathway and patient journey in presbyopia are outlined, and various treatment options are analyzed. The data reviewed herein reveals significant gaps in the provision of vision correction for this common condition, with a paucity of effective, non-invasive treatment options broadly accessible to presbyopic individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.